IMDNA provides scientific, technical, and non-regulatory support for development and scale-up of manufacturing processes for molecular research reagents, qPCR/RT-qPCR assay components, master mixes, primer/probe formulations, controls, buffers, immunoassay reagents, research-use kits, and related laboratory products within IMDNA's technical capabilities. Support can include process mapping, formulation transfer, raw-material strategy, batch-size expansion, mixing and hold-time studies, filling and dispensing workflows, in-process controls, pilot-scale manufacturing, process-risk review, yield and variability assessment, technical documentation, troubleshooting, technology transfer, and scale-up support.
Scale-up is not simply multiplying a laboratory recipe by a larger batch factor. Mixing dynamics, surface-to-volume ratio, order of addition, temperature control, raw-material variability, hold time, fill accuracy, equipment geometry, process timing, environmental conditions, and sampling can all behave differently as manufacturing scale changes. IMDNA approaches scale-up as a structured process-understanding exercise designed to identify critical variables, preserve product attributes, and establish a practical control strategy appropriate to the intended research product.
FDA's process-validation lifecycle framework states that process design is based on knowledge gained during development and scale-up, and that successful process control depends on understanding sources of variation, their impact on product attributes, and how that variation will be controlled. These principles are useful well beyond regulated drug manufacturing when building reproducible research-reagent production processes.
Define the characteristics that must be preserved during scale-up, such as concentration, composition, pH, activity, fluorescence behavior, amplification performance, stability, homogeneity, or other product-specific attributes.
Document each manufacturing step, material input, equipment interaction, hold point, transfer, filtration, mixing, filling, labeling, storage, and quality check.
Identify raw materials, equipment, operators, environment, timing, temperature, mixing, filling, and other variables that may influence product performance.
Define practical in-process checks, material controls, operating ranges, sampling points, and finished-product testing appropriate to the product and manufacturing stage.
Use laboratory, engineering, pilot, and production-scale data to understand whether the process behaves consistently as volume and equipment change.
Support can begin with an early formulation, an existing small-batch process, a client-developed product requiring transfer, or an established process that needs improved consistency or higher output.
Break the process into defined operations such as weighing, dissolution, mixing, incubation, filtration, formulation, aliquoting, filling, sealing, labeling, storage, and testing.
Translate a laboratory formulation into a controlled production recipe with defined material quantities, sequence of addition, mixing conditions, temperatures, hold times, and final adjustment steps.
Review material identity, grade, supplier, lot variability, storage, stability, preparation, concentration, incoming documentation, and potential impact on product performance.
Support stepwise scale increase rather than relying only on proportional arithmetic, with attention to equipment capacity, mixing, transfer losses, sampling, hold time, and fill requirements.
Evaluate order of addition, mixing speed/time, solution behavior, viscosity, foaming, temperature effects, concentration uniformity, and sampling location where relevant.
Support studies to determine whether bulk material or process intermediates remain acceptable during realistic manufacturing pauses before the next unit operation.
Support liquid-dispense accuracy, dead-volume considerations, container compatibility, fill-volume consistency, reagent settling, plate/tube format, sealing, and labeling workflow.
Help define practical checks for pH, volume, concentration, weight, temperature, appearance, homogeneity, instrument readings, fill volume, or other product-specific attributes.
Use intermediate-scale batches to identify process behavior that may not be visible at bench scale before larger manufacturing runs are attempted.
Track expected and actual yield, transfer loss, hold-up volume, scrap, overfill, filtration loss, and other sources of material loss that become important during scale-up.
Investigate batch-to-batch variability, mixing issues, fill inconsistency, reagent instability, contamination risk, unexpected assay behavior, or other scale-dependent technical problems.
Prepare process descriptions, master manufacturing instructions, batch records, scale-up reports, risk reviews, technical-transfer documents, and training materials for the receiving manufacturing team.
IMDNA's support model follows the process from laboratory formulation through pilot manufacturing, controlled scale transition, technical transfer, and continuing process review.
ICH Q8 and FDA process-validation principles emphasize linking product quality attributes with the process parameters that can affect them. For research reagents, the same science-based approach can help identify which variables require tighter control during scale-up.
Concentration of salts, enzymes, oligonucleotides, antibodies, stabilizers, preservatives, detergents, dyes, buffers, or other formulation components.
Buffer composition, ionic strength, Mg or other cofactors, pH adjustment, temperature dependence, and batch-to-batch reproducibility where relevant.
PCR amplification performance, enzyme activity, antibody binding, control signal, fluorescence response, or other product-specific functional attributes.
Uniform distribution of active components across the bulk before and during filling, particularly for multi-component or particulate formulations.
Short-term hold, freeze-thaw, storage temperature, light exposure, shipping stress, container effects, and longer-term stability as appropriate to the product.
Dispense volume, concentration consistency, overfill strategy, dead volume, evaporation, and container-to-container variation.
Workflow segregation, materials, equipment cleanliness, environmental practices, nuclease or amplicon contamination risks, and other product-relevant controls.
Finished-product testing should demonstrate that the manufacturing process preserves the assay or reagent function required for the intended research application.
FDA notes that laboratory- and pilot-scale experiments can help predict commercial-process behavior but that the relevance of scale models depends on understanding the differences between them. At larger scale, seemingly minor physical changes can alter product uniformity, transfer efficiency, temperature equilibration, and functional performance.
| Scale-Up Variable | Why It Can Change with Scale | IMDNA Support May Include |
|---|---|---|
| Mixing | Larger vessels change mixing time, vortex behavior, shear, mass transfer, and homogeneity. | Mixing-time studies, sampling at multiple locations, order-of-addition review, homogeneity assessment. |
| Temperature | Larger volumes heat and cool more slowly and may develop gradients. | Temperature-profile review, equilibration studies, time limits, cooling/heating workflow development. |
| Surface / Volume Ratio | Contact with vessel walls, air interface, adsorption, and evaporation can shift as vessel geometry changes. | Container/equipment comparison, recovery testing, hold studies, material compatibility review. |
| Transfer Loss | Tubing, pumps, vessels, dead volume, filters, and larger equipment can increase unrecovered material. | Yield mapping, hold-up analysis, transfer-sequence optimization, expected-yield ranges. |
| Dispensing / Filling | Longer fill times can introduce settling, evaporation, temperature drift, or concentration differences. | Fill-volume studies, beginning/middle/end sampling, bulk agitation strategy, dispense verification. |
| Process Time | Preparation, transfer, filtration, and filling often take longer at larger scale. | Hold-time studies, process-timing limits, intermediate stability review, scheduling optimization. |
| Equipment Geometry | Bench vessels and production tanks may not produce equivalent flow patterns or contact surfaces. | Equipment-fit review, pilot studies, scale-transition experiments, technical risk assessment. |
| Sampling | A single aliquot may not represent a larger heterogeneous bulk. | Sampling-plan support, location/time-point comparison, homogeneity verification. |
The exact parameters depend on the product and manufacturing process.
Scale-up should be supported by data showing that larger-batch performance remains acceptable relative to the defined product and process objectives.
For qPCR and RT-qPCR products, manufacturing variability can directly influence amplification efficiency, Cq values, low-level detection, fluorescence separation, internal-control performance, and multiplex balance. Scale-up should therefore preserve both formulation characteristics and functional molecular performance.
Support controlled dilution, concentration calculations, order of addition, mixing, aliquoting, contamination control, traceability, and functional comparison of oligonucleotide pools.
Preserve target-to-target primer/probe ratios and evaluate whether scaled preparation changes weak-target sensitivity, channel behavior, or assay competition.
Support component addition, temperature control, stabilization, mixing, aliquoting, freeze-thaw considerations, and functional qPCR performance where within project scope.
Support bulk preparation, dilution, homogenization, target concentration, matrix selection, dispensing, stability, and lot-to-lot functional comparison.
Support solution preparation, pH/conductivity review where relevant, mixing, filtration, container compatibility, fill-volume control, and downstream molecular-performance testing.
Use appropriately designed qPCR/RT-qPCR runs, controls, reference materials, or other functional testing to determine whether scaled production preserves intended research performance.
Pilot batches create an important bridge between bench formulation and larger production. FDA's lifecycle guidance recognizes laboratory- and pilot-scale studies as important sources of process knowledge. Pilot work can reveal equipment, mixing, transfer, fill, hold-time, and yield issues before larger batches are committed.
Use intermediate batch sizes to evaluate whether the process behaves consistently before increasing to the intended production scale.
Determine whether available mixers, vessels, pumps, pipetting systems, dispensers, filters, cold-storage systems, or other equipment are suitable for the proposed process.
Measure real preparation, mixing, transfer, hold, filling, and packaging times so the manufacturing procedure reflects actual operational conditions.
Evaluate beginning/middle/end bulk or fill samples, different vessel locations, or other points needed to understand process uniformity.
Build realistic expected-yield ranges from laboratory and pilot data rather than assuming theoretical yield will be achieved.
Document variables studied, observations, deviations, results, technical rationale, identified risks, and recommended production conditions.
ICH Q10 and FDA/ICH Q7 emphasize controlled documentation, change management, process understanding, and lifecycle knowledge. Even for research-use manufacturing, structured records improve reproducibility, investigation, transfer, and scale-up decisions.
Define raw materials, quantities, sequence of operations, equipment, process conditions, in-process checks, hold points, fill instructions, and storage conditions.
Capture actual lot numbers, quantities, operators, dates, equipment, process measurements, yields, deviations, and completed manufacturing steps.
Link critical materials and lots to each manufacturing batch so unexpected performance can be investigated systematically.
Record the measurements that demonstrate whether the process remained within established operating ranges.
Document departures from planned conditions, assess technical impact, investigate where needed, and determine appropriate follow-up.
Track formulation, supplier, equipment, scale, process, packaging, test method, and workflow changes with scientific rationale.
WHO technology-transfer guidance identifies development/production transfer, analytical-method transfer, training, premises/equipment assessment, documentation, qualification, and validation as major elements of successful manufacturing transfer. Each project is unique, so the transfer package should be tailored to the product, process, receiving unit, and intended use.
Transfer formulation history, development rationale, critical variables, operating ranges, known failure modes, and scale-up observations.
Compare equipment, utilities, materials, environmental conditions, staff experience, storage, filling, testing, and workflow between sites.
Provide controlled process instructions and batch-record templates adapted to the receiving site's equipment and operating workflow.
Support transfer of the functional or analytical methods used to evaluate in-process and finished-product performance.
Provide technical walkthroughs, process rationale, critical-step training, troubleshooting guidance, and receiving-team support.
Support pilot or bridging batches and technical comparison to determine whether the receiving site reproduces intended process and product performance.
ICH Q10 states that changes should be evaluated by appropriately knowledgeable teams, supported by prospective criteria, and reviewed after implementation to confirm that objectives were achieved without adverse impact on product quality. This lifecycle mindset is especially important as manufacturing scale, suppliers, equipment, or formulations evolve.
Assess whether a change in supplier, grade, lot, concentration, or material specification may alter the process or finished-product performance.
Review mixing geometry, dispensing characteristics, temperature control, contact materials, capacity, and process timing when equipment changes.
Determine whether another batch-size increase changes mixing, hold time, yield, fill duration, sampling, or functional assay performance.
Support targeted comparison when component concentration, stabilizer, buffer, enzyme, oligonucleotide pool, control matrix, or other formulation features change.
Use manufacturing experience to reduce variability, improve yield, simplify workflow, shorten process time, improve fill consistency, or strengthen robustness.
Compare performance before and after the change and document whether the intended improvement was achieved without creating new limitations.
IMDNA provides scientific, technical, manufacturing-process-development, scale-up, pilot-production, troubleshooting, documentation, technology-transfer, and non-regulatory support based on the needs of each project. Support may include assistance with process mapping, formulation transfer, raw-material strategy, batch-size expansion, mixing and hold-time studies, filling workflows, in-process controls, pilot batches, yield analysis, process-risk review, manufacturing documentation, change assessment, troubleshooting, scale-up, and technical transfer.
Where appropriate, IMDNA may provide development batches, pilot manufacturing, research-use reagent manufacturing, process studies, technical documentation, analytical/QC support, training resources, and process-transfer assistance through its scientific, technical, and laboratory-experienced team.
IMDNA is not a regulatory, licensing, accreditation, certification, legal, governmental, or inspecting authority. IMDNA does not represent general process-development or scale-up support as formal GMP validation, regulatory approval, manufacturing authorization, or certification unless the specific activity is conducted under an applicable quality system and the required formal responsibilities have been independently established.
The customer or responsible manufacturing organization remains responsible for determining the regulatory classification and requirements applicable to its own product; approving specifications, critical attributes, process parameters, batch records, release criteria, validation requirements, quality-system controls, and final manufacturing decisions; and obtaining any required regulatory, licensing, accreditation, or other authorization.
FDA, ICH, and WHO manufacturing references on this page are used as science- and risk-based frameworks for process understanding, scale-up, technology transfer, documentation, and lifecycle thinking. Their regulatory applicability depends on product category, intended use, manufacturing stage, jurisdiction, and quality system. Inclusion of these references does not imply that every IMDNA project is subject to pharmaceutical GMP requirements.
References to governmental, regulatory, standards-development, scientific, or professional organizations are provided for general informational purposes only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA or its services.
The following references support the general principles of process development, scale-up, process understanding, control strategy, lifecycle validation, technology transfer, documentation, and change management. Several are pharmaceutical-manufacturing frameworks; their scientific principles are informative, but their formal regulatory applicability depends on the product and intended use.
Tell IMDNA about your product or formulation, current batch size, raw materials, critical assay performance, manufacturing steps, equipment, fill format, desired production scale, stability constraints, QC strategy, and technical challenges. Our scientific and technical team can help build a scale-up plan covering process mapping, pilot batches, critical variables, in-process controls, mixing, filling, yield, functional testing, documentation, troubleshooting, technology transfer, and continued process improvement.